case_images: PMC10944892_01
case_images: Skin prick test: negative for atezolizumab and pembrolizumab. Intra-dermal test: positive at 0.06 mg/mL and 0.6 mg/mL of atezolizumab (IDT; 0.06 mg/mL; wheal, 3.8 x 3.5; flare, 7 x 7 and 0.6 mg/mL; wheal, 5.3 x 4.9; flare, 12 x 8), and negative for pembrolizumab.
case_images: fonc-14-1273043-g001.jpg
case_images: PMC10944892_01_fonc-14-1273043-g001.jpg
case_images: f1
case_images: The skin prick test with atezolizumab at a concentration of 60 mg/mL was negative, and the intradermal test was positive at 0.06 mg/mL and 0.6 mg/mL (IDT, 0.06 mg/mL; wheal, 3.8 x 3.5; flare, 7 x 7 and 0.6 mg/mL; wheal, 5.3 x 4.9; flare, 12 x 8) ( Figure 1 ). The skin prick test (25 mg/ml) and intradermal (0.25 mg/ml) test were performed with pembrolizumab, and both were negative ( Figure 1 ).
case_images: Abdominal non-contrast computed tomography after three cycles of pembrolizumab. (A) Enlarged metastatic lymphadenopathies in aorto-caval, and para-aortic on CT conducted August 22, 2022. (B) A partial response was observed on restaging CT conducted October 18, 2022. White circle means "metastatic LNs".
case_images: fonc-14-1273043-g002.jpg
case_images: PMC10944892_01_fonc-14-1273043-g002.jpg
case_images: f2
case_images: After the 11th chemotherapy session, a partial response was still maintained ( Figure 2 ).